European Commission Approved BioNTech and Pfizer Vaccine

Vaccination against coronavirus in the EU will begin shortly, all countries will receive BioNTech / Pfizer at the same time and on equal terms, the European Commission said. A few hours after the the BNT162b2 coronavirus vaccine certification, developed by the German company BioNTech and the American Pfizer, the European Commission finally approved the drug. Soon the EU countries will be able to start vaccination, the department said on Monday evening, December 21. In turn, the head of the European Commission, Ursula von der Leyen (Ursula von der Leyen) announced that the vaccine will be available simultaneously to all EU countries and all of them will receive the drug under the same conditions. Earlier in the day, the European Medicines Agency (EMA) approved the BioNTech and Pfizer vaccine for use in the EU. The head of the EMA, Emer Cook, said that the drug is presumably effective against the new coronavirus strain, which began to spread rapidly in England in the last week. BioNTech and Pfizer vaccine The BNT162b2 vaccine is already in use in a number of countries, including the UK, USA, Canada, Bahrain, Saudi Arabia and Mexico. In Germany and many other EU countries, vaccinations are planned to begin before the end of December. According to research results, the effectiveness of the drug reaches 95%, in the case of people over 65 years old - more than 94%. Serious side effects have not yet been identified in trial participants, more than 40% of whom are people aged 56 to 85 years. In trials of a vaccine that minimizes the risk of severe COVID-19 viral pneumonia, 43.5 thousand people participated, about half of them received a placebo.